Factors Associated with Depression During the Perimenopausal Transition

Gibbs, Zoe; Lee, Stuart; Kulkarni, Jayashri

doi:10.1016/j.whi.2013.07.001

Cited by 39 publications

(27 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies suggest that previous depressive periods might increase the risk of depression during natural menopausal . In accordance with this, we found that previous users of antidepressants were more likely to use antidepressants following bilateral oophorectomy compared to never‐users thus identifying previous use of antidepressants as a risk factor for use of antidepressants following bilateral oophorectomy.…”

Section: Discussionsupporting

confidence: 87%

Use of antidepressants in women after prophylactic bilateral oophorectomy: A Danish national cohort study

et al. 2020

View full text Add to dashboard Cite

Objective: To investigate the association between prophylactic bilateral oophorectomy and use of antidepressants in women with a family history of cancer.Methods: Nationwide population-based cohort study using Danish National Registries including women oophorectomized due to a family history of cancer (n = 2,002) and an age matched reference group (n = 18,018). Analyses were stratified by age at time of bilateral oophorectomy and use of hormone replacement therapy (HRT).Results: Women oophorectomized at age ≤ 45 years were more likely to use antidepressants from the first year after bilateral oophorectomy (OR = 1.34; 95 % CI: 1.08-1.65) compared to the reference group. Women oophorectomized at age 46-55 years and at age >55 years had no significantly increased use of antidepressants (OR = 0.90; 95 % CI: 0.68-1.18 and OR = 1.14; 95 % CI: 0.81-1.61). The increased use of antidepressants in women oophorectomized at age ≤ 45 years was limited to women treated with HRT (OR = 1.51; 95 % CI: 1.18-1.94) whereas women oophorectomized at age ≤ 45 years not treated with HRT had no increased use of antidepressants (OR = 1.03; 95 % CI: 0.70-1.51). Conclusions:Women oophorectomized due to a family history of cancer at age ≤ 45 years were more likely to use antidepressants after bilateral oophorectomy.The increased use of antidepressants was limited to women treated with HRT. The study calls for further large-scale studies to understand how bilateral oophorectomy and concomitant HRT affects risk of depression in women with a family history of cancer. K E Y W O R D SCancer, oncology, family history of cancer, prophylactic bilateral oophorectomy, antidepressants, hormone replacement therapy 1 | BACKGROUND Women with a family history of breast and/or ovarian cancer have a substantially increased risk of these cancers 1,2 and germline mutations in BRCA 1 and 2 genes leads to a cumulative breast cancer risk of above 60 % and an ovarian cancer risk of between 10-45 %. 3 Cancer risk increases considerably with age. 3 Thus, prophylactic bilateral oophorectomy is recommended prior to natural menopause leading to a significant reduction in risk of cancer. 4,5 High risk of hereditary cancer is associated with an increased frequency of disabling concerns and cancer related worries, which may be relieved by bilateral oophorectomy. 6 Contrary to this, surgical menopause leads to troublesome vasomotor symptoms. 6-8 and sexual dysfunction 6-9 Furthermore, studies indicate that bilateral oophorectomy may have mood-lowering effects. 10-13 Depression seems to be related to declining levels of estrogen, and sudden estrogen withdrawal in perimenopause 14,15 and postpartum 16 is associated with an increased risk of depression. In contrast to this,

show abstract

Section: Discussionsupporting

confidence: 87%

Use of antidepressants in women after prophylactic bilateral oophorectomy: A Danish national cohort study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Some interventions may only work at certain stages of the transition, therefore, a clear and accurate defi nition would facilitate this research. Table 9.1 defi nes menopause according to the Stages of Reproductive Aging Workshop (STRAW) (Soules et al 2001 ) enhanced with additional data regarding broader hormonal changes, behavioral correlates and known predictors to date (Ganz et al 2011 ;Soules et al 2001 ;Hale and Burger 2009 ;Freeman et al 2008 ;Gracia et al 2007 ;Nappi et al 2010 ;Buijs et al 2008 ;Cohen et al 2002 ;Gibbs et al 2013 ;Sigmon et al 2004 ;Stone et al 2013 ). Most of the data are drawn from the general population with a sprinkling of data from the population with breast cancer.…”

Section: Menopause: More Than Estrogenmentioning

confidence: 99%

Symptoms: Menopause, Infertility, and Sexual Health

Barton

Ganz

2015

Improving Outcomes for Breast Cancer Survivors

View full text Add to dashboard Cite

By 2022, the number of survivors is expected to grow to nearly 18 million. Therefore, addressing acute and chronic negative sequelae of a cancer diagnosis and its treatments becomes a health imperative. For women with a history of breast cancer, one of the common goals of treatment and prevention of recurrence is to reduce circulating concentrations of estradiol, especially in women with hormone receptor positive breast cancer. Hormone deprivation after a diagnosis of breast cancer impacts physiological targets other than in the breast tissue and can result in unwanted side effects, all of which can negatively impact quality of life and function and cause distress. Symptoms that are most strongly linked by evidence to hormone changes after cancer diagnosis and treatment include hot flashes, night sweats, sleep changes, fatigue, mood changes, and diminishing sexual function, including vaginal atrophy (decreased arousal, dryness and dyspareunia), infertility, decreased desire and negative self-image. Weight gain and resulting body image changes are often concomitants of the abrupt onset of treatment-induced menopause. The purpose of this chapter is to briefly review what is known about the advent of premature menopause in women treated for breast cancer, menopausal symptoms that are exacerbated by endocrine treatments for breast cancer, and the associated concerns of hot flashes and related menopausal symptoms, sexual health and fertility issues. We will discuss limitations in the current research and propose strategies that address current limitations in order to move the science forward.

show abstract

“…Обнаружена связь (p < 0,01) депрессии с рядом детерминант [22]: социально-демографическими (климактерий, женский пол), соматогенно-органическими (соматические, ýндокринные и психовегетативные нарушения), социально-стрессовыми (снижение функционирования в разных сферах, изменение образа жизни), психологическим реагированием в виде ýмоциональной чувствительности, смены настроения. Это положение совпадает с результатами исследования, подтвердившего вклад в ýтиологию менопаузальной депрессии негативно-потенцирующего социального стрессора, снижающего стрессоустойчивость, повышающего тревогу и приводящего к ДЭ (негативные жизненные события: болезнь, развод, утрата, увольнение) [23].…”

Section: роль стрессорно-дезадаптирующих факторов в формировании кдunclassified

Depressive disorders in women of climacteric age (review of foreign literature for 2012–2016)

Бохан¹,

Лукьянова²,

Симуткин³

2018

Bûll. sib. med.

View full text Add to dashboard Cite

Objective:to systematically review foreign literature and interpret results of the review. Tasks: to review foreign papers where factors are considered which provoke development of depression: hormonal, psychological, social as well as neuromediators, hormonal and immune disturbances in depressive disorders in women with physiological climacteric and climacteric syndrome; issues of differential diagnostics of depressions, psychopharmaco- and psychotherapy with subsequent evaluation of clinical efficiency; personality profile of pateints with affective psychopathology.Methods of search: by keywords in Web of Science Core Collection database across foreign journals (2012– 2016). Criteria of inclusion of papers in the review are determined by themes of studies: 1) women of climacteric age; 2) presence of depression or depressive symptoms; 3) presence of climacteric disturbances. In the abstract-bibliographic and scientometric database Web of Science Core Collection 70 bibliographic sources are selected across foreign journals between 2012 and 2016, including journals with high Impact Factor. Studies included in the review are performed at the university clinics, specialized centers. Clinical and sociodemographic characteristics of female patients meet the criterion of compatibility. Most discussed papers are devoted to study of clinical and social-psychological factors of development of climacteric depression. In a number of papers the efficiency of antidepressant therapy, alternative methods and supplementary therapy in women with depressive disorders, climacteric disturbances and co-occurring physical diseases is shown. Most works are performed with involvement of questionnaires (sociodemographic data, anamnesis) and international clinical scales. The main results of the discussed papers are outlined in thematic rubrics.Conclusion. The European and American papers are used in this review more frequently; studies from Asian countries are used more seldom. Reviewed foreign publications reflect worldwide trend to increase of climacteric depression (CD) in the female population with presence in the anamnesis of adolescent (psychoendocrine alteration) and postpartum depression, premenstrual syndrome. Low timely diagnostics of depressions, high incidence rate of somaticized CD are noted. In the structure of climacteric syndrome the psychoemotional disturbances predominate above neurovegetative and metabolic-endocrine or are combined with vegetative dysfunction. The participation in formation of CD (with predominance of mild/moderate severity) of neurohormonal, genetic, biochemical, social-environmental, psychological factors is shown. In the reviewed sources low mood, loss of previous priorities, decrease of productivity and concentration of attention, position of being unprotected, dependence, lack of confidence, self-humiliation, repentance, unbelief in future, insomnias, hypo-/hyperrexia with change of body mass are described in CD but there are no publications on suicidal ideation. It is indicated that CD can flow with hysteric- and nosophobic, somatohypochondriac and asthenohypochondriac component. The authors consider that somatization as an experience of climacteric stress leads to somaticized CD with accent on physical symptoms and repression of depression and anxiety although an association of specific somatic nosologies with symptoms of CD is not described. The association of CD with social-environmental factors (gender, education, profession, social position, financial wealth) is discussed, achievement of the woman is considered as a actor of reduction of CD risk. The authors are highly interested in search for genetic markers (heredity, suicides in relatives), impairment of neuromediator exchange (neurotransmitters serotonin, dopamine, adrenaline, and noradrenaline), neuromorphologic alterations in brain sensorimotor cortex (motor function, attention, perception, memory, and emotional-motivational response), hormonal disturbances (neuroendocrine and metabolic) and psychoneuroimmunological patterns of association with CD. Psychopharmacotherapy in CD is constructed with account for depressive symptoms (antidepressants of activating/sedative action in long-term maintenance regime), background and co-occurring diseases (adequate and pathogenetic and immunotherapy) with involvement in case of absence of contraindications of substitutive hormonotherapy (estrogen, progesterone). Beyond conventional schemes of the therapy the alternative therapy of CD (acupuncture, yoga, phytoestrogen collections, and food additives) is discussed. For heightening the efficiency and safety of the therapy of CD the training in detection of CD signs both for female patients and nurses, psychologists, social workers is proposed.

show abstract

Factors Associated with Depression During the Perimenopausal Transition

Cited by 39 publications

References 54 publications

Use of antidepressants in women after prophylactic bilateral oophorectomy: A Danish national cohort study

Use of antidepressants in women after prophylactic bilateral oophorectomy: A Danish national cohort study

Symptoms: Menopause, Infertility, and Sexual Health

Depressive disorders in women of climacteric age (review of foreign literature for 2012–2016)

Contact Info

Product

Resources

About